NASDAQ:CLBS - Caladrius Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Caladrius Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.61 +0.01 (+0.38 %) (As of 12/10/2019 01:47 AM ET) Add Compare Today's Range$2.53Now: $2.61▼$2.6850-Day Range$2.07MA: $2.46▼$2.9352-Week Range$2.00Now: $2.61▼$5.44Volume18,700 shsAverage Volume30,549 shsMarket Capitalization$27.14 millionP/E RatioN/ADividend YieldN/ABeta1.63 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Caladrius Biosciences, Inc is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Miscellaneous health & allied services, not elsewhere classified Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CLBS Previous Symbol CUSIPN/A CIK320017 Webhttp://www.caladrius.com/ Phone908-842-0100Debt Debt-to-Equity RatioN/A Current Ratio5.06 Quick Ratio5.06Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$35.28 million Price / Sales0.77 Cash FlowN/A Price / Cash FlowN/A Book Value$3.81 per share Price / Book0.69Profitability EPS (Most Recent Fiscal Year)($1.67) Net Income$-16,170,000.00 Net MarginsN/A Return on Equity-56.79% Return on Assets-46.69%Miscellaneous EmployeesN/A Outstanding Shares10,400,000Market Cap$27.14 million Next Earnings Date3/12/2020 (Estimated) OptionableOptionable Receive CLBS News and Ratings via Email Sign-up to receive the latest news and ratings for CLBS and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CLBS Rates by TradingView Caladrius Biosciences (NASDAQ:CLBS) Frequently Asked Questions What is Caladrius Biosciences' stock symbol? Caladrius Biosciences trades on the NASDAQ under the ticker symbol "CLBS." How were Caladrius Biosciences' earnings last quarter? Caladrius Biosciences Inc (NASDAQ:CLBS) announced its quarterly earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by $0.04. View Caladrius Biosciences' Earnings History. When is Caladrius Biosciences' next earnings date? Caladrius Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Caladrius Biosciences. What price target have analysts set for CLBS? 4 brokerages have issued 1-year price targets for Caladrius Biosciences' shares. Their forecasts range from $6.00 to $18.50. On average, they anticipate Caladrius Biosciences' stock price to reach $10.42 in the next twelve months. This suggests a possible upside of 299.1% from the stock's current price. View Analyst Price Targets for Caladrius Biosciences. What is the consensus analysts' recommendation for Caladrius Biosciences? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Caladrius Biosciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Caladrius Biosciences. What are Wall Street analysts saying about Caladrius Biosciences stock? Here are some recent quotes from research analysts about Caladrius Biosciences stock: 1. According to Zacks Investment Research, "Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York. " (8/14/2019) 2. Chardan Capital analysts commented, "Maintaining Perform rating after better-than-expected 1Q results, but expect continued heavy investment and uncertainty around Homes. IMT EBITDA was 76%/71% above Opco/Street, significantly higher on two non-recurring accounting adjustments, and management raised the low-end of FY guidance for PA and IMT, suggesting re-acceleration. However, Offers bought 898 homes and sold 414, resulting in an increase of homes in inventory from 509 in 4Q to 993 in 1Q. This suggests some homes were older than 90 days and this was evidenced by inventory doubling over the quarter from $163M in 4Q to $325M. We remain on the sidelines on uncertainty around terminal unit economics and management pushing its five-year targets to longer" than originally assumed." (5/12/2019) Has Caladrius Biosciences been receiving favorable news coverage? News coverage about CLBS stock has been trending positive recently, according to InfoTrie. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Caladrius Biosciences earned a coverage optimism score of 2.6 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Caladrius Biosciences. Are investors shorting Caladrius Biosciences? Caladrius Biosciences saw a drop in short interest in the month of November. As of November 15th, there was short interest totalling 39,800 shares, a drop of 23.6% from the October 31st total of 52,100 shares. Based on an average daily volume of 13,300 shares, the short-interest ratio is currently 3.0 days. Approximately 0.4% of the shares of the company are short sold. View Caladrius Biosciences' Current Options Chain. Who are some of Caladrius Biosciences' key competitors? Some companies that are related to Caladrius Biosciences include Fresenius Medical Care AG & Co. (FMS), Davita (DVA), Progyny (PGNY), Tivity Health (TVTY), American Renal Associates (ARA), Catasys (CATS), HemaCare (HEMA), Emmaus Life Sciences (EMMA), Baudax Bio (BXRX), Pacific Health Care Organization (PFHO), BioRestorative Therapies (BRTX) and American Caresource (GNOW). What other stocks do shareholders of Caladrius Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Caladrius Biosciences investors own include Brainstorm Cell Therapeutics (BCLI), HubSpot (HUBS), Karyopharm Therapeutics (KPTI), Energy Transfer LP Unit (ET), Consolidated Water (CWCO), Inovio Pharmaceuticals (INO), AcelRx Pharmaceuticals (ACRX), CBL & Associates Properties (CBL), Ford Motor (F) and Stryker (SYK). Who are Caladrius Biosciences' key executives? Caladrius Biosciences' management team includes the folowing people: David J. Mazzo, President, Chief Executive Officer & DirectorJoseph Talamo, CFO, Principal Accounting Officer & Senior VPDouglas W. Losordo, Chief Medical Officer & Executive Vice PresidentGreg Berkin, Vice President-Information TechnologyJohn D. Menditto, VP-Investor Relations & Corporate Communications How do I buy shares of Caladrius Biosciences? Shares of CLBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Caladrius Biosciences' stock price today? One share of CLBS stock can currently be purchased for approximately $2.61. How big of a company is Caladrius Biosciences? Caladrius Biosciences has a market capitalization of $27.14 million and generates $35.28 million in revenue each year. The biotechnology company earns $-16,170,000.00 in net income (profit) each year or ($1.67) on an earnings per share basis. View Additional Information About Caladrius Biosciences. What is Caladrius Biosciences' official website? The official website for Caladrius Biosciences is http://www.caladrius.com/. How can I contact Caladrius Biosciences? Caladrius Biosciences' mailing address is 110 ALLEN ROAD 2ND FLOOR, BASKING RIDGE NJ, 07920. The biotechnology company can be reached via phone at 908-842-0100 or via email at [email protected] MarketBeat Community Rating for Caladrius Biosciences (NASDAQ CLBS)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 279 (Vote Outperform)Underperform Votes: 239 (Vote Underperform)Total Votes: 518MarketBeat's community ratings are surveys of what our community members think about Caladrius Biosciences and other stocks. Vote "Outperform" if you believe CLBS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLBS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/10/2019 by MarketBeat.com StaffFeatured Article: What is the Fibonacci sequence?
